Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. In January 2026, Nyxoah announced a new investment to expand its Belgian manufacturing capacity with a nearly 2,000-square-meter facility with a state-of-the-art cleanroom at LégiaPark in the Liège region to meet growing demand for its Genio therapy in the United States and international markets. The company is positioned as an innovative challenger in hypoglossal nerve stimulation therapy facing patent litigation from established competitor Inspire Medical Systems.
Cyborg Score Rationale
The company achieved revenue of €1.3 million, marking a 73% year-over-year increase in Q2 2025, demonstrating early commercialization traction post-FDA approval. However, the company faces a patent infringement lawsuit from Inspire Medical Systems, the established leader in hypoglossal nerve stimulation for OSA, with such litigation typically consuming significant financial and management resources and potentially impeding commercial momentum at this critical launch juncture.
Top Insights
FDA approval achieved August 2025; Genio system cleared for moderate-to-severe OSA patients (AHI 15-65), unlocking primary U.S. addressable market after years in development
Manufacturing expansion underway in Belgium (January 2026) signals confidence in demand scaling; company controls both U.S. contract manufacturing and new in-house capacity
Patent infringement lawsuit from Inspire Medical Systems (market leader) creates near-term litigation risk requiring significant management attention and potential licensing costs
Strong gross margins (61.8%) and €43M+ cash position provide runway for commercialization, but rising operating expenses (€20.7M in Q2 2025) and R&D restructuring (Israel to U.S./Belgium) indicate investment intensity
Named Competitors
Inspire Medical Systems — Established leader in hypoglossal nerve stimulation (HGNS) for moderate-to-severe OSA; primary competitive threat
ResMed CPAP and PAP Devices — Market-leading positive airway pressure devices for OSA; non-invasive alternative modality